PRECIGEN pipeline
Innovation
by Design
Our pipeline brings to life transformative programs built on our cutting-edge AdenoVerse® and UltraCAR-T® platforms.
AdenoVerse Pipeline
| Product | Platform | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Approved |
| PAPZIMEOS (zopapogene imadenovec-drba) | AdenoVerse | RRP | ||||||
| PRGN-2009 (+pembrolizumab) | AdenoVerse | HPV-associated Cancers |
UltraCAR-T Pipeline
| Product | Platform | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Approved |
| PRGN-3006 | UltraCAR-T | AML, MDS | ||||||
| PRGN-3005 | UltraCAR-T | Ovarian Cancer | ||||||
| PRGN-3007 | UltraCAR-T | Hematological & Solid Tumors |
Expanded Access Policy
Download PolicyFor physicians seeking pre-approval access to one of our investigational therapies, please review our expanded access policy. For expanded access inquiries, please contact us at expandedaccess@precigen.com.